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EMG1Bowen–Conradi syndrome (BCS) is a lethal autosomal recessive disorder caused by a D86G substitution in the
protein, Essential for Mitotic Growth 1 (EMG1). EMG1 is essential for 18S rRNA maturation and 40S ribosome
biogenesis in yeast, but no studies of its role in ribosome biogenesis have been done in mammals. To assess
the effect of the EMG1 mutation on cell growth and ribosomal biogenesis in humans, we employed BCS patient
cells. The D86G substitution did not interferewith EMG1nucleolar localization. In BCS patient lymphoblasts, cells
accumulated in G2/M, resulting in reduced proliferation rates; however, patient ﬁbroblasts showed normal pro-
liferation. The rate of 18S rRNAprocessingwas consistently delayed in patient cells, although this did not lead to a
difference in the levels of 40S ribosomes, or a change in protein synthesis rates. These results demonstrate that as
in yeast, EMG1 inmammals has a role in ribosomebiogenesis. The obvious phenotype in lymphoblasts compared
to ﬁbroblasts suggests a greater need for EMG1 in rapidly dividing cells. Tissue-speciﬁc effects have been seen in
other ribosomal biogenesis disorders, and it seems likely that the impact of EMG1 deﬁciency would be larger in
the rapidly proliferating cells of the developing embryo.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Bowen–Conradi syndrome (BCS, MIM #211180) is a lethal autoso-
mal recessive disorder common in the Hutterite population of the
Canadian Prairies and the United States Great Plains. Infants with BCS
display central nervous system defects including mental retardation
and profound psychomotor retardation. Common physical manifesta-
tions include pre- and postnatal growth retardation, microcephaly,
prominent nose, micrognathia, rockerbottom feet and ﬂexion contrac-
tures of the joints. The average age at death is 13 months, but the
exact cause is unclear and seems to be a result of severe failure to thrive.
With a prevalence of 1/355 live births, this disease is a signiﬁcant con-
cern for the Hutterites [1–4], but has not yet been found outside this
population. We identiﬁed a single base mutation in EMG1 (Essential
for Mitotic Growth 1) that results in an Asp86Gly (D86G) substitution, Essential for Mitotic Growth 1;
ne; m1acp3-ψ, N1-methyl-N3-
per minute; IRES, internal ribo-
edical Genetics, The University
Canada. Tel.: +1 204 789 3218.
istead),
01@yahoo.com (N. Patel),
. This is an open access article underin the EMG1 protein as the cause of BCS, and showed that this mutation
results in an unstable protein, as evidenced by a substantial reduction of
EMG1 in BCS patient ﬁbroblasts and lymphoblasts [5,6]. Little is under-
stood about the role of EMG1 in mammalian cells; however research
conducted in yeast has shown that this protein is essential for cell sur-
vival and growth, and plays a role in the assembly of the small subunit
of the ribosome [7,8].
Ribosome synthesis and assembly is an extremely complex and
energy-intensive cellular process. In fact, in proliferating yeast cells,
roughly half of all RNA polymerase II transcription initiation events
are on ribosomal protein genes, and approximately 80% of the total
RNA in the cell is ribosomal [9]. A mature eukaryotic ribosome is com-
posed of the small subunit, containing the 18S rRNA and 33 ribosomal
proteins, and the large subunit, containing the 28S, 5.8S and 5S rRNAs
and 49 ribosomal proteins. The 18S, 5.8S and 28S rRNAs are all
expressed as a single polycistronic 45S precursor transcript which is
processed to yield the mature forms, while the 5S rRNA is transcribed
separately. Biogenesis of a fully functioning ribosome involves the coor-
dinated efforts of all three RNA polymerases, and roughly 200 assembly
proteins and 75 small nucleolar RNAs (snoRNAs) which aid in the mat-
uration and assembly process [10–12]. These factors modify nascent
rRNA concurrentwith transcription, including cleavage of the precursor
transcript by endo- and exonucleases, 2′-O ribose methylation,
pseudouridylation, base methylation, and assembly with ribosomalthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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bility and function. Understandably, ribosome biogenesis is tightly reg-
ulated, and the TP53 pathway is a powerful checkpoint for ribosome
assembly. In a healthy cell, the E3-ubiquitin ligase MDM2 binds and
ubiquitylates TP53, targeting it for degradation to maintain low levels
of the protein. In the event of aberrant ribosome biogenesis, free ribo-
somal proteins which are unable to assemble into mature ribosomes
bind and segregate MDM2, leading to the accumulation of TP53
[13–16]. Subsequent cell-cycle arrest or apoptosis ensures that only
cells with intact ribosome biogenesis machinery can proliferate.
In yeast, the precursor 45S rRNA is modiﬁed co-transcriptionally by
the small subunit processome, a complex rivaling the small subunit it-
self in size, which contains the U3 snoRNA and at least 40 proteins
[17,18]. Emg1, the yeast homologue of the proteinmutated in BCS, is as-
sociated with the small subunit processome [17] and catalyzes the
transfer of a methyl group from a S-adenosylmethionine (SAM) donor
to the N1 of a pseudouridine at position 1191 of yeast 18S rRNA (1248
in human 18S rRNA), forming the hyper-modiﬁed N1-methyl-N3-(3-
amino-3-carboxypropyl) pseudouridine (m1acp3-ψ) [19,20]. Other
roles for Emg1 during ribosome biogenesis have been proposed, includ-
ing recruitment of the ribosomal small subunit protein RPS19 to thema-
turing ribosome, and removal of snR57, the snoRNA component of the
snoRNP responsible for the 2′-OH ribose methylation of G1570 in
yeast 18S rRNA [21]. Most recently, it was posited that Emg1 may act
as a chaperone in 18S rRNA folding [22]. As Saccharomyces cerevisiae
and human EMG1 are 51% identical at the protein level, and human
EMG1 complements yeast Emg1 deﬁciency, it is probable that they
have similar functions [8].
Most small subunit processome proteins are essential for cell surviv-
al [17,18,23], and depletion causes speciﬁc ribosome biogenesis deﬁ-
ciencies. In yeast, depletion of Emg1 causes defects in the production
of 18S rRNA [17], and processing of precursor rRNA to mature 18S
rRNA is delayed in cells lacking the hypermodiﬁcation of pseudouridine
m1acp3-ψ [24]. In addition, cells incorporating the equivalent BCS-
causing mutation in Emg1 show reduced growth rates [20]. Assuming
similar functions for yeast and human EMG1, we hypothesized that
the reduction in EMG1 protein levels seen in BCS patients would result
in altered 18S rRNA processing, and therefore deﬁcient biogenesis of the
small ribosomal subunit. The reduction of healthy ribosomeswould lead
to reduced protein synthesis rates concomitant with slower rates of cell
proliferation. Because the levels of ribosome proteins are tightly regu-
lated and linked to rRNA transcription to ensure optimal ribosome bio-
genesis rates, we expected that disruption in ribosome protein levels
would also lead to TP53 stabilization. A delay in rRNA processing
could consequently be sufﬁcient to disturb proper ribosome biogenesis
during periods of increased cell proliferation, such as embryonic devel-
opment. Similar defects have been found in the ribosomopathies in
humans, a clinically variable group of disorders which are associated
with mutations in ribosome proteins and biogenesis factors (reviewed
in [25–27]). Here, we show that cell proliferation rates were signiﬁcant-
ly reduced in patient lymphoblasts concomitant with a cell cycle delay
at G2/M, without detectably altering steady-state levels of the small
subunit of the ribosome, 18S rRNA levels, or protein synthesis rates. In
addition, processing of 18S rRNA was slightly, but consistently, delayed
in both lymphoblasts and ﬁbroblasts from BCS patients.2. Materials and methods
2.1. Study subjects
Lymphoblast or ﬁbroblast cell lines from patients were generated as
part of a previous study to map the BCS gene [3]. Signed informed con-
sent was obtained for all participants. This study was approved by the
Health Research Ethics Board at the University of Manitoba. Unless oth-
erwise stated, all experiments were performed in both lymphoblastsand ﬁbroblasts. For each cell type, two patient cell lines were compared
with two to three age-matched control cell lines.
2.2. Cell culture
Fibroblast cells were maintained in minimal essential medium
(alpha modiﬁcation) (Invitrogen, Sigma) with 10% fetal bovine
serum and lymphoblasts were maintained in RPMI medium 1640
(Invitrogen, Sigma) with 15% fetal bovine serum, at 37 °C and 5% CO2.
All media contained 100 U penicillin/ml and 100 μg streptomycin/ml
(Invitrogen).
2.3. Immunocytochemistry
Cells were grown on glass coverslips, were rinsed with phosphate
buffered saline (PBS) (1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 150 mM
NaCl, pH 7.4), and were ﬁxed in 4% paraformaldehyde for 15 min at
room temperature. After three washes in PBS, quenching was per-
formed in 50 mM ammonium chloride in PBS for 10 min, followed by
another three washes in PBS. Permeabilization was done with 0.1%
Triton X-100 in PBS for 10 min, the coverslips were washed three
times in PBS, and the cells were incubated in 100 μl blocking solution
(3% bovine serum albumen, 0.05% Tween in PBS) for 60 min. Primary
antibodies (100 μl) were diluted in blocking solution as follows: EMG1
rabbit polyclonal at 1:500 (Protein Tech Group), NOP14 mouse poly-
clonal at 1:100 (Novus), ﬁbrillarin mouse monoclonal at 1:500
(Abcam) and incubated for 1 h. Incubation with secondary antibodies
diluted at 1:1000 (Alexa Fluor, Molecular Probes) was performed for
30 min. The coverslips were rinsed twice with water, and incubated
for 30 s in Hoechst 33342 diluted 1 μl in 100 ml of water to stain nuclei.
The coverslips were washed twice in water, Prolong Gold Antifade Re-
agent (Molecular Probes) was applied to a glass slide, and the coverslip
was inverted on top, cured overnight, and sealed with clear nail polish.
2.4. Assessment of cell proliferation rate
Cell proliferation rates were determined for each cell line using
an MTT assay kit (Cell Titer 96 Non-Radioactive Cell Proliferation
Assay kit, Promega) following the manufacturer's instructions. Brieﬂy,
1 × 104 cells were seeded into the wells of 24-well plates and grown
at 37 °C for 0, 24, 48 or 72 h. At each time point, the cells were incubated
at 37 °C for 4 h in a 150 μl MTT reagent, followed by 1 h in 1 ml of stop
solution. The absorbance of eachwell was read by a spectrophotometer
at 570 nm. Alternatively, cellswere countedmanually at twelve hour in-
tervals using a hemacytometer. Dead cells were excluded using trypan
blue.
2.5. Cell cycle analysis
Cells were harvested and washed twice with wash buffer (0.1% fetal
bovine serum in PBS) to derive a single cell suspension. Equal numbers
of cells were suspended in 1 ml of buffer, and 3 ml of−20 °C absolute
ethanol were added dropwise with light vortexing to ﬁx cells while
minimizing clumping. Cells were ﬁxed a minimum of 3 h at 4 °C and
stored at room temperature until the day of analysis. Fixed suspensions
were washed twice with PBS, suspended in 1 ml of staining solution
(40 μg/ml propidium iodide, 0.2 ml RNase A, 0.1% Triton X-100 in
PBS), and incubated at room temperature for 30 min. Samples were
placed on ice until analysis by ﬂow cytometry, using a MoFlo XDP cell
sorter (Beckman Coulter) and Modﬁt LT software for cell cycle analysis
(Verity Software House).
2.6. Detection of ribosomal subunits
Ribosomal subunits were detected using a modiﬁed method [28].
Cells in log phase of growth were washed with PBS and pelleted by
35J. Armistead et al. / BBA Clinical 1 (2014) 33–43centrifugation. Equal numbers of cells (2 × 106 for ﬁbroblasts and 1.7 ×
107 for lymphoblasts) were lysed in ribosome extraction buffer (10mM
Tris pH 7.4, 1% Igepal, 0.5% sodium deoxycholate, 2 mM [low] or 15mM
[high] MgCl2, 0.1 M KCl, 0.5 mg/ml Heparin, 80 U/ml RNAseOut
[Invitrogen], 1 mM DTT, 1/250 protease inhibitor stock [Sigma]) to ex-
tract the ribosomes. After a 15 minute incubation on ice, nuclei and
cell debriswere pelleted by centrifugation at 12 000×g for 2min. A por-
tion of the lysatewas saved as an input fraction. Approximately 300 μl of
the ribosome lysate was applied to the top of a 10–45% sucrose gradient
in sucrose gradient buffer (Tris pH 7.4, 0.1 M KCl, MgCl2 equal to ribo-
some extraction buffer, 2 mM EDTA [low Mg gradients only]) prepared
in polyallomer ultracentrifuge tubes. Gradients were separated by cen-
trifugation at 36 000 rpm for 3 h at 4 °C with the brake off. Gradients
were collected with an ISCO gradient collector by pumping 60% sucrose
in the bottomwhile the gradient was collected from the top and absor-
bance was monitored at 254 nm, and 0.5 ml fractions were collected.
The tracing produced was scanned, and the area under the curve was
determined using theMeasure function in Axiovision software. Average
60S/40S ratios for wild type and BCS cells were compared using
Student's t-test.
2.7. Immunoblot analysis
Proteins were isolated from cultured cells by lysis in a modiﬁed
radioimmunoprecipitation assay (RIPA) buffer (1% tert-octylphenoxy
(poly) oxyethelene ethanol [IGEPAL]; 0.5% sodium deoxycholate; 0.1%
SDS; 1.9 mM NaH2PO4; 8.1 mM Na2HPO4; 150 mMNaCl), supplement-
ed 1 in 500 with a protease inhibitor cocktail (Sigma). RIPA-insoluble
proteins were separated by centrifugation for 10 min in a micro-
centrifuge at 10 000 ×g, leaving the RIPA-soluble proteins in the super-
natant. Protein concentrations were determined using either the
Bradford assay (Bio-Rad) or the bicinchoninic acid assay (ThermoScien-
tiﬁc). Equal amounts of protein (20–25 μg) were separated at 160 V
using 10% SDS-PAGE gels. Proteins were transferred to a nitrocellulose
membrane in N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer
at pH 11 (0.01 M CAPS, 10%methanol) or in Tris–glycine transfer buffer
(25mMTris, 192mM glycine, 20%methanol) at 100 V for 1 h according
to a modiﬁedmethod [29]. Themembrane was blocked in 5% skimmilk
in Tris buffered saline Tween (TBST) (20 mM Tris pH 7.4; 0.15 M NaCl;
0.1% Tween) for 1 h. Individual proteins were detected using a primary
antibody diluted in blocking solution overnight at 4 °C. The membrane
was washed three times with TBST, incubated with horseradish perox-
idase (HRP)-conjugated secondary antibody for 1 h,washed, and visual-
ized using the Immobilon western chemiluminescent HRP substrate
(Millipore). Primary antibody dilutions were used as follows: RPL7 rab-
bit polyclonal at 1:5000 (Bethyl laboratories), RPS19 rabbit polyclonal at
1:3000 (Proteintech Group), TP53 2B2.68 mouse monoclonal at 1:2000
(Santa Cruz), p21/WAF1/Cip1 mouse monoclonal at 1:250 (Millipore),
and β-actin mouse monoclonal at 1:5000 (Sigma). The secondary
donkey anti-rabbit and donkey anti-mouse antibodies (Jackson
Immunoresearch) were diluted to 1:20 000.
2.8. Isolation of total RNA and gel electrophoresis
Total RNA was isolated from ﬁbroblasts or lymphoblasts using the
TRIzol reagent (Invitrogen) and following manufacturer's instructions.
Cellswere lysed in the culture vessel by the addition of TRIzol and pipet-
ting up and down multiple times. Cells grown in suspension were
pelleted and the supernatant removed before lysis. Chloroform
(0.2 ml) was added to lysates and shaken by hand for 15 s to mix,
then incubated at room temperature for 3 min. Samples were centri-
fuged at 12 000 ×g 15 min at 4 °C, and the upper aqueous phase was
transferred to a new tube. RNA was precipitated in 0.5 ml isopropanol,
and rotated for 10 min at room temperature. After centrifugation, the
supernatant was decanted, and the RNA pellet was washed with 1 ml
75% ethanol. The ethanol was removed, the pellet was air dried, andthe RNA was resuspended in diethylpyrocarbonate-treated water and
stored at−80 °C. To prepare RNA for separation by gel electrophoresis,
equal volumes of RNA and NorthernMax-Gly Sample Loading Dye
(Ambion) were mixed and incubated at 50 °C for 30 min to eliminate
secondary structures. RNA samples were then separated by gel electro-
phoresis in a 1% agarose BPTE gel (100 mM PIPES, 300 mM Bis-Tris,
10 mM EDTA pH 8.0) in 1× BPTE buffer at 5 V per cm.
2.9. Determination of 28S/18S rRNA ratio
For each cell line, three independent samples of RNAwere analyzed
by capillary electrophoresis using the RNA 6000Nano LabChip Kit in the
Agilent 2100 Bioanalyzer according to the manufacturer's instructions.
Samples (1 μl) were analyzed in duplicate compared to 1 μl of ladder.
The quality of RNA separation was assessed by the resolution of the in-
dividual peaks in the ladder, and the area of each peak, as well as the
28S/18S rRNA ratios, were determined using the Agilent Bioanalyzer
software.
2.10. Metabolic labeling and analysis of ribosomal RNA
Pulse-chasemetabolic labeling of rRNAwas conducted essentially as
described by Pestov et al. [28]. 32P-orthophosphate labeling was
employed in both ﬁbroblast and lymphoblast cell lines, and repeated
using 3H methyl-methionine in ﬁbroblasts. For 32P-orthophosphate
labeling, equal numbers of ﬁbroblasts (~2.5 × 105 cells per well) were
cultured overnight in six-well plates in DMEM (Invitrogen). The
following morning, cells were starved for 1 h in phosphate-free
DMEM (Sigma) supplemented with dialyzed serum, then 10 μCi/ml
32P-orthophosphate (Perkin Elmer) was added for a pulse period of
40 min. Cells were washed twice in complete DMEM and incubated in
cold medium. Cells were harvested at 20 minute intervals using the
TRIzol reagent (Invitrogen), and RNA was isolated as described above.
Incorporated radioactivity was determined in counts per minute
(CPM) using a scintillation counter (Beckman Coulter), and equal
counts from each sample were mixed with glyoxal loading dye
(Ambion). RNA species were separated by gel electrophoresis as
above. The gel was dried and exposed to a phosphor storage screen
(Bio-Rad) which was subsequently scanned using a phosphorimager
(Bio-Rad). Band intensities were quantiﬁed using Image Lab software
(Bio-Rad).
For 3H methyl-methionine labeling, ﬁbroblasts were treated essen-
tially as for 32P-orthophosphate labeling, except that cells were starved
for 30 min in cysteine/methionine-free DMEM (Invitrogen) supple-
mented with 5 mM cysteine, dialyzed serum, and glutamine. Cells
were labeled with 50 to 75 μCi/ml L-[methyl-3H] methionine (Perkin
Elmer) for 30 min, then chased in complete DMEM supplemented
with 5 mM methionine for the indicated time periods. Following gel
electrophoresis, RNA was transferred to a positively charged nylon
membrane (GE Healthcare) in BPTE using the Genie apparatus
(Idea Scientiﬁc) at 12 V for 1 h at 4 °C. Themembranewas then exposed
to a phosphor storage screen (Screen K/Tritium, Bio-Rad).
2.11. Assessment of protein synthesis rate
Cells were incubated for 4 h at 37 °C with media containing 150 μCi
35S Cys/Met (Perkin Elmer), washed with ice-cold PBS, and lysed in
500 μl of radioimmunoprecipitation assay (RIPA) buffer (1% tert-
octylphenoxy (poly)oxyethelene ethanol [IGEPAL]; 0.5% sodium
deoxycholate; 0.1% SDS; 1.9 mM NaH2PO4; 8.1 mM Na2HPO4; 150 mM
NaCl) supplemented with protease inhibitors (Sigma). After cen-
trifugation, a 20 μl aliquot of the supernatant was mixed with 100 μl
of 40 mg/ml bovine serum albumin and 1 ml of ice-cold 10% trichloro-
acetic acid (TCA). After incubating on ice for 45 min, the precipitated
protein was collected on a 1.2 μm glass microﬁber ﬁlter (GF/C,
Whatman) using a vacuum manifold. The ﬁlters were washed twice
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dioactivity was determined in CPM using a liquid scintillation counter.
The protein concentration for each sample was determined using the
bicinchoninic acid assay (Pierce). Protein synthesis rate was then calcu-
lated as the amount of incorporated radioactivity in CPM per μg of pro-
tein. Cycloheximide (Sigma) was used as a negative control to inhibit
protein synthesis [30].
2.12. Statistical analyses
Statistical signiﬁcancewas assessed using Student's two-tailed t-test
calculated by GraphPad Prism software. A p value of less than 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. EMG1 co-localizes with ribosome biogenesis factors
EMG1, the protein product of the gene mutated in Bowen–Conradi
syndrome, has been implicated in ribosome biogenesis in yeast and
human cells, although most work to determine its function has been
performed in yeast [7,8,19,20]. To evaluate the sub-cellular localization
of EMG1 relative to other ribosome biogenesis factors in human cells,
immunoﬂuorescence was used to detect EMG1, ﬁbrillarin, and NOP14.
As expected, EMG1 was localized primarily to the nucleolus of both
BCS patient and control ﬁbroblasts, as evidenced by its co-localization
with ﬁbrillarin, an rRNA methyltransferase found in the dense ﬁbrillar
component of the nucleolus [31] (Fig. 1A–C). NOP14, a small ribosomal
subunit assembly factor which has been shown to interact with EMG1
[7], was detected in the nucleolus and in the cytoplasm, in agreement
with previous analysis of its localization in yeast cells by biochemical
fractionation and by immunoﬂuorescence [7] (Fig. 1E). EMG1 largely
co-localized with the nucleolar fraction of NOP14 (Fig. 1D–F). EMG1 in
lymphoblasts displayed a similar nucleolar localization (not shown).
These results support a role for EMG1 in ribosome biogenesis, and, im-
portantly, indicate that EMG1 localization is unaffected in BCS patient
cells.
3.2. Cell proliferation and cell cycle are delayed in BCS lymphoblasts but not
in ﬁbroblasts
BCS patients display severe pre- and post-natal growth retardation,
and Emg1 is essential for cell growth in yeast [7,8] and in mice [32].
To determine if growth of BCS patient cells was altered due to the
EMG1mutation, the MTT assay was employed to compare proliferation
rates in BCS patient and age-matched control lymphoblasts or ﬁbro-
blasts. This assay employs a yellow tetrazolium salt substrate which is
reduced to a purple insoluble formazan complex by the mitochondria.
The amount of color produced is therefore directly proportional to the
number of metabolically active cells. BCS patient lymphoblasts showed
signiﬁcantly slower proliferation rates over a 72-hour period relative to
control lymphoblasts (Fig. 2A), with a mean doubling time of 51.90 ±
2.03 h, compared to a mean of 38.40 ± 1.38 h for control lymphoblasts
(Fig. 2C). We found no signiﬁcant difference in the proliferation rates
between unaffected control ﬁbroblasts and BCS patient ﬁbroblasts
(Fig. 2B). The mean doubling time for control ﬁbroblasts was 46.73 ±
3.10 h, and 43.02 ± 4.68 h in BCS ﬁbroblasts (Fig. 2E). To rule out the
possibility that the lymphoblast MTT assay data were due to changes
in cell metabolism and not in cell numbers, cells weremanually counted
at twelve hour intervals, using trypanblue to excludedeador dying cells
(Fig. 2D). BCS lymphoblasts proliferated signiﬁcantly slower than con-
trol cells, conﬁrming the MTT assay results.
It has been shown previously that errors in biogenesis of the small
ribosomal subunit cause a stall in the cell cycle at G1/S, due to a check-
point which assesses adequate ribosome numbers [13,17,33]. A length-
ening of G1/S phase could explain the slower cell proliferation rate, ascells would take longer to progress through a complete cell cycle.
To determine if the cell cycle was altered in BCS, cell sorting of
propidium iodide-stained cells was performed. This assay separates
cells into G1, S, or G2/M populations based on their DNA content. Unex-
pectedly, lymphoblasts from BCS patients had a signiﬁcantly in-
creased proportion of cells in G2/M (Fig. 2F), with no signiﬁcant
difference in any other phase of the cell cycle. On the other hand,
cell cycle was not altered in BCS patient ﬁbroblasts when compared
to controls (Fig. 2G). These data suggest that a stall at the G2/M
checkpoint results in a longer cell cycle in BCS patient lymphoblasts,
causing reduced proliferation rates, but that patient ﬁbroblasts are
not appreciably affected.
3.3. Levels of the small ribosomal subunit are normal at steady state in BCS
patient cells
In order to determine if the deﬁciency of EMG1 protein seen in BCS
patient cells was causing an alteration in the synthesis of the small ribo-
somal subunit, the relative amounts of the small and large ribosomal
subunits were evaluated. Lysates prepared from equal numbers of pa-
tient and unaffected control lymphoblasts andﬁbroblasts,were separat-
ed in a sucrose gradient and the ribosomal subunits were detected by
absorbance as they were collected from the gradient (Fig. 3A, B). Ribo-
somal proteins of the small and large subunits were monitored by im-
munoblot in collected fractions to verify separation (Fig. 3C, D). The
ratio of the large subunit to the small subunit was compared between
BCS patients and controls, and no signiﬁcant difference was found
(Fig. 3E, F), either in the presence of low (Fig. 3A, B) or high (not
shown) levels of Mg2+, which is required for the association of the sub-
units. These data indicate that at steady state, the small subunit of the ri-
bosome is at normal levels in BCS patient cells relative to the large
subunit. No difference in total ribosome subunit levels was evident be-
tween control and patient cells (data not shown), ruling out the possibil-
ity that total ribosome synthesis is down-regulated in BCS patients.
3.4. The rate of 18S rRNA processing is delayed in BCS patient cells
The amount of steady-state 18S rRNA in cells from BCS patients was
then assessed. Total RNA was isolated from either ﬁbroblasts or lym-
phoblasts from BCS patients or normal, age-matched controls, and was
analyzed using the RNA 6000 Nano LabChip Kit in the Agilent 2100
Bioanalyzer. Examples of the resultant electropherograms are shown
in Fig. 4A–B. The area under the curve for each peak was calculated,
and total amounts of 18S were evaluated relative to 28S rRNA. In each
case, there were no signiﬁcant differences in the ratio of 28S rRNA to
18S rRNA between any of the samples (Fig. 4C, D).
Although the steady-state levels of rRNA remain unaffected, it is pos-
sible that the processing rate of precursor 45S to mature 28S and 18S
rRNA is delayed in BCS patient cells. This was previously shown in the
ribosomopathy Shwachman–Diamond syndrome, where sucrose gradi-
ent analysis showed similar steady-state levels of ribosomal subunits,
yet the formation of mature rRNA was signiﬁcantly slower in
Shwachman–Diamond syndrome patient ﬁbroblasts [34]. To evaluate
rRNA processing rates, pulse-chase analysis was employed using either
32Pi or 3H-methyl methionine to label nascent rRNA. Using this tech-
nique, it is possible to follow the transformation of precursor 45S
rRNA to its mature 28S (Fig. 5, arrows) and 18S rRNA forms (arrow-
head) over time. Following a pulse of radioactive label, the cells were
chased in cold media, and samples were collected at regular intervals.
Ribosomal RNA was isolated and separated using gel electrophoresis,
then visualized using autoradiography (Fig. 5). Using Image Lab soft-
ware to quantify band intensity, a consistent reduction in labeling of
18S rRNA in BCS patient cells was found (Fig. 5B and E), while 28S
rRNA was unaffected (Fig. 5C and F). Although this difference was
only statistically signiﬁcant at a speciﬁc point in processing (see time
20 min of 18S rRNA in ﬁbroblasts, Fig. 4B; and time 40 min of 18S
Fig. 1. EMG1 co-localizes with ribosome biogenesis factors in nucleoli of human cells. (A) Fibroblasts were ﬁxed using 4% formaldehyde and stained with anti-EMG1 (green) and anti-
ﬁbrillarin (red) in control and patient cells. DNA was visualized by staining with Hoechst 33342 (blue). Themerged photo shows the co-localization of EMG1 and the dense ﬁbrillar com-
ponent protein ﬁbrillarin, in nucleoli of both control and BCS cells. Original magniﬁcation, 63×; scale bar = 20 μm. (B) Fibroblasts were stained with anti-EMG1 (green) and anti-NOP14
(red). Themerged photo shows the co-localization of EMG1 and the small subunit processome protein NOP14 in nucleoli. Similar localizationwas found in normal control and BCS patient
cells. Original magniﬁcation, 63×; scale bar = 20 μm.
37J. Armistead et al. / BBA Clinical 1 (2014) 33–43rRNA in lymphoblasts, Fig. 4E), the reduction was consistent through
several independent experiments, employing both the 32Pi and the 3H
methyl-methionine labels, and in both lymphoblasts and ﬁbroblasts.
This, together with the fact that steady state rRNA levels were normal,
indicates that overall rRNA production occurs at a normal rate in BCS
cells, and that processing of 18S rRNA is instead delayed. This delay
does not detectably affect steady-state levels of 18S or 28S rRNA, nor
does it alter steady-state levels of the ribosomal subunits.3.5. Protein synthesis rates are unaffected in BCS patient ﬁbroblasts
A delay in the 18S rRNA processing could result in sub-optimal ribo-
some function, and perturb overall protein synthesis rates.We therefore
examined the rate of protein synthesis in each ﬁbroblast cell line by the
incorporation of 35S Cys/Met over a four-hour period, calculated as the
amount of incorporated radioactivity in CPM per μg of protein
(Fig. 6A). Similar results were found for BCS patient and unaffected
Fig. 2. BCS patient lymphoblasts display reduced cell proliferation rates and cell cycle delay at G2/M. (A, B) Cell proliferation rates, evaluated using theMTT assay, in lymphoblasts (A) and
ﬁbroblasts (B). At 24-hour intervals, cells seeded in a 96-well plate were incubatedwith theMTT reagent for 4 h, lysed, and the absorbancewas read at 570 nm. The fold change relative to
time 0was plotted for each time point. Themean of four independent experiments, each performed in triplicate, is shown for the lymphoblasts, and three experiments for the ﬁbroblasts.
BCS lymphoblast results were signiﬁcantly lower than controls at 48 h (*p b 0.01), and at 72 h (**p b 0.001); error bars show SEM. (C, E) Doubling time of lymphoblasts (C) and ﬁbroblasts
(E). Doubling timewas calculated from the results of theMTT assay performed in (A) and (B). In BCS lymphoblasts, doubling timewas signiﬁcantly longer (*p b 0.0001). (D) Lymphoblast
cell concentrations in cells per milliliter, counted at twelve hour intervals. BCS lymphoblast numbers were similar to control numbers until the 36 hour time point, and were signiﬁcantly
lower than controls from 36 to 72 h (*p b 0.01). The mean of two independent experiments, each performed in duplicate, and SEM are shown. (F, G) Cell cycle analysis of lymphoblasts
(F) and ﬁbroblasts (G). Cells were treated with propidium iodide and sorted based on DNA content. In the lymphoblasts, the percentage of cells in G2/M phase was signiﬁcantly higher in
BCS cells than in control cells (*p = 0.00185). The mean of three independent experiments and SEM are shown.
38 J. Armistead et al. / BBA Clinical 1 (2014) 33–43control ﬁbroblasts, indicating that the delay in 18S rRNA processing
does not alter the rate of translation by the ribosome. This is consistent
with the conclusions that the delay in 18S rRNA processing is transient,
and does not affect steady-state levels of the ribosomal subunits. Given
that the ribosomal RNA and subunit levels were similarly unaffected in
BCS patient lymphoblasts, the protein synthesis rate experiments were
performed on ﬁbroblasts only.
3.6. TP53 is not stabilized in BCS patient cells
Because the dysregulation of ribosome biogenesis has been shown
to lead to TP53 stabilization and cell cycle arrest [13–16], levels of
TP53 protein in BCS patient cells and unaffected controls were com-
pared using immunoblot analysis. At steady state, TP53 protein levels
varied between cell lines, with no clear difference between BCS pa-
tient cells and unaffected controls in lymphoblasts (Fig. 6B) orﬁbroblasts (not shown). To assess downstream targets of TP53, we
examined levels of p21 in lymphoblasts using an anti-p21 antibody,
and again found no differences between control and patient cell lines
(Fig. 6C). The absence of consistent TP53 stabilization or induction of
downstream p21, suggests that the cell proliferation defect in BCS
lymphoblasts is not mediated by TP53. This is consistent with
the fact that an Emg1 knockout mouse is not rescued by Trp53
ablation [32].
4. Discussion
In yeast, a reduction in levels of the ribosome biogenesis enzyme
Emg1 causes a decrease in 18S rRNA levels with a corresponding accu-
mulation of its immediate precursor in the rRNA processing pathway
[7]. This lack of 18S rRNA leads to an imbalance between the large and
small ribosomal subunits, which in turn causes a reduction in protein
Fig. 3.Ribosomal subunit levels at steady-state are normal in BCS patient cells. (A, B) Sucrose gradient separation of 40S and60S ribosomal subunits in lymphoblasts (A) andﬁbroblasts (B).
Ribosomal subunits were detected following sucrose gradient separation by absorbance at 254 nm, and examples of the resultant tracings are shown. (C, D) Fractions were collected at
regular intervals and probed by immunoblot analysis for ribosomal proteins using anti-RPS19 and anti-RPL7 antibodies to verify the separation of the small (RPS) and large (RPL) subunits.
(E, F) The area under the curve was determined for individual peaks, and the ratio of large to small subunit was calculated. No signiﬁcant difference between unaffected control and BCS-
affected cells was found in lymphoblasts (E) and ﬁbroblasts (F). The mean of six individual experiments and SEM are shown.
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EMG1 levels are severely reduced in BCS patient lymphoblasts and ﬁ-
broblasts, we would see a corresponding decrease in cell proliferation
and protein synthesis rates due to a deﬁciency of small ribosomal sub-
units. Instead, we found slower proliferation rates in BCS lymphoblasts,
accompanied by an increase in the proportion of cells in G2/M, while
neither was affected in BCS ﬁbroblasts. A consistent, transient delay in
18S rRNA processing in both ﬁbroblasts and lymphoblasts was found,
although it did not result in a detectable alteration of steady-state levels
of 18S rRNA or small ribosomal subunits. Protein synthesis rates were
also unaffected in BCS patient ﬁbroblasts.
The reduced proliferation rate, observed only in the BCS lympho-
blasts, can be explained by a signiﬁcant lengthening of the cell cycle in
G2/M, whichwas also found only in lymphoblasts.While rRNA process-
ing defects typically cause G1 arrest [13,17,33], an increase in the per-
centage of cells in G2/M phase has been reported in cells depleted
of dyskerin, the protein responsible for the X-linked form of the
ribosomopathy dyskeratosis congenita [35,36]. In addition, changes in
ribosomal protein RPL13a expression can induce cell cycle arrest at
G2/M [37], mutations in RNAse MRP causing cartilage hair hypoplasialead to cell cycle delay in anaphase [38], and a mutation in pescadillo
in zebraﬁsh, a gene implicated in ribosome biogenesis, disrupts oligo-
dendrocyte formation due to failure to progress from S phase tomitosis
[39]. The stall at G1/S seen inmany cases of ribosome biogenesis disrup-
tion has been shown to be the result of a checkpoint which veriﬁes that
adequate numbers of ribosomes are present before proceedingwith the
cell cycle. We found that steady-state levels of the ribosome subunits
are normal in BCS cells, which may explain why they are able to prog-
ress through the G1/S checkpoint. A second checkpoint may exist
preventing cells from progressing through mitosis in the absence of
proper ribosome biogenesis.
Intriguingly, in the ribosomopathy X-linked dyskeratosis congenita,
ribosomes lacking pseudouridine are deﬁcient in internal ribosomal
entry site (IRES)-dependent translational initiation due to failure of
the ribosome to bind to the IRES sequence [40,41]. In general, cap-
dependent translation is inhibited at the beginning of mitosis in favor
of the translation of mRNAs containing IRES elements, including one
isoform of cyclin-dependent kinase 11, which is necessary for progres-
sion through M phase [42,43]. In X-linked dyskeratosis congenita, it is
thought that pseudouridine-deﬁcient ribosomes are unable to
Fig. 4. Ribosomal RNA levels at steady-state are normal in BCS patient cells. (A, B) Total RNA was isolated from unaffected control and BCS-affected lymphoblasts (A) and ﬁbroblasts (B),
and separated by capillary chromatography using the 6000 RNANano kit in an Agilent Bioanalyzer. The resulting electropherograms show the 18S and 28S peaks, aswell as a smaller peak
which encompasses the 5S, 5.8S, and tRNA. (C, D) 28S/18S ratios for lymphoblasts (C) andﬁbroblasts (D). The area of eachpeakwas calculated by theAgilent software, and the ratios of 28S
to 18S rRNA were calculated. The mean of three individual experiments, performed in triplicate, and SEM are shown. No signiﬁcant difference was found between the control and BCS
patient cells.
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translation of cell-cycle related proteins. In the same vein, it is conceiv-
able that changes in rRNA methylation or folding occasioned by the
D86G substitution in EMG1 alter the speciﬁcity of the ribosome in
such a way that it can no longer recognize or bind IRES elements efﬁ-
ciently. Further support for this hypothesis comes from the fact that
IRES-dependent mRNA translation is down-regulated in mice express-
ing mutated Rps19, the gene most commonly associated with Dia-
mond–Blackfan anemia [44]. It has been postulated that EMG1
promotes RPS19 binding to the nascent ribosome [21,22]. Further
study is needed to determine if defects in IRES-mediated translation
lead to the delay or failure of progression through G2/M seen in BCS pa-
tient lymphoblasts.
To determine if a defect in ribosome biogenesis was causing the
delay at G2/M and the concomitant reduction in cell proliferation
rates, the processing of precursor 45S rRNA to its mature formswas ex-
amined using pulse-chase metabolic labeling. We detected a slight but
reproducible decrease in the processing rate of 18S rRNA in both ﬁbro-
blasts and lymphoblasts, evidence that a defect in ribosome biogenesis
underlies Bowen–Conradi syndrome. As EMG1 has more than one pro-
posed role in 18S rRNA processing, it is difﬁcult to determine the exact
nature of the defect. Given that EMG1 is a methyltransferase, the use
of 3H-methyl methionine as a label makes it impossible to determine
if the reduction in detectable radioactivity is the result of reduced
rRNA production, or if rRNA is produced at normal levels but is under-
methylated. Several lines of evidence point to the former scenario.
First, yeast Emg1 bearing the equivalent mutation of the BCS protein
conserves its rRNAmethyltransferase activity in an in vitro methylation
assay [20] despite causing a reduction in cell growth rates. Second,
Emg1 mutants that are unable to bind the methyl donor SAMmaintain
normal ribosome biogenesis [45]. Finally, similar results were observed
using inorganic phosphate as a radiolabel, which incorporates into theRNA backbone and does not affect rRNA methylation. It is therefore
likely that the reduction in EMG1 causes a delay in 45S to 18S rRNA
processing via its role in RPS19 recruitment or rRNA folding rather
than its catalytic activity. Despite the fact that a delay in processing
was observed in both ﬁbroblasts and lymphoblasts, steady-state ratios
of 60S to 40S ribosomal subunits were unaffected in both cell types,
and consequently protein synthesis rates were also unchanged. This is
similar towhat was found in the ribosomopathy Shwachman–Diamond
syndrome, where a reduction in rRNA production in patient ﬁbroblasts
was not associatedwith an imbalance in 60S, 40S, or 80S ribosomal sub-
unit levels at steady state [34]. Given the transient nature of the 18S
rRNA defect observed in BCS patient cells, it is unlikely that a 60S/40S
subunit ratio imbalance would be detected using sucrose gradient anal-
ysis of ribosome subunits at steady state, as we did here.
Underlining the importance of the TP53 checkpoint in proper
ribosome biogenesis, previous studies have shown that removal of
Trp53 can rescue the defect in certainmousemodels of ribosomopathies
[46,47]. However, crossing Trp53−/−mice with Emg1+/−mice failed to
rescue the pre-implantation growth arrest phenotype of EMG1 knock-
outs [32]. Taken together with our TP53 immunoblot studies which
did not show stabilization of TP53 in BCS patient cells, we concluded
that the EMG1 defect likely does not activate the TP53 pathway. Al-
though the link between the TP53 pathway and ribosome biogenesis
has been exploited in animal models of ribosome biogenesis, recent
studies have shown variable responses to TP53 inhibition or knockout.
In Rpl38, Rps19, and Rpl11mutant mice, the phenotype is refractory to
TRP53 inhibition [44,48]. In a zebraﬁshmodel of Shwachman–Diamond
syndrome, ablation of the TP53 checkpoint in sbds knockdownﬁsh ame-
liorates the skeletal phenotype and improves the overall health of the
embryos [49]. However, the pancreas hypoplasia is not rescued, sug-
gesting that the phenotype is only partially mediated by the TP53 path-
way. Similarly, TP53 knockdown in a Diamond–Blackfan anemia model
Fig. 5.Ribosomal RNAprocessing is delayed in BCS patient cells. (A) Inﬁbroblasts, nascent rRNAwasmetabolically labeled using (methyl-3H)methionine for 30min, and RNAwas isolated
at twenty minute intervals to follow the processing rate of the large 45S rRNA precursor to the mature 18S (arrowhead) and 28S species (arrow). Equal counts were separated on a 0.7%
agarose gel, and transferred to a positively-charged nylon membrane. The membrane was exposed to a phosphor storage screen, which was scanned using a phosphorimager. The pre-
cursor 45S rRNA, the 28S and 18S mature species, and the intermediates are indicated on the left side of the diagram. A representative image of three independent experiments is
shown. (B, C) The intensity of each band in (A) was quantiﬁed using Image Lab software. The graphs indicate the mean density in arbitrary units of the 18S (B) and 28S rRNA (C)
bands at each time point, and the error bars represent standard deviation. For this experiment, the average of three control cell lines and two BCS cell lines are shown. The 18S rRNA
level was signiﬁcantly reduced in BCS cells at the 20 minute time point (*p = 0.0287). (D) A representative image of an rRNA processing experiment in lymphoblasts. The experiment
was performed essentially as in (A), except the rRNA was labeled with 32Pi for a twenty minute pulse. Following gel electrophoresis to separate the RNA species, the gel was dried and
directly exposed to a phosphor storage screen. (E) and (F) show the intensity of each band. The 18S rRNAwas signiﬁcantly reduced in BCS cells at the 40 minute time point (*p= 0.0292).
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erythropoietic defect [50,51]. The selective contribution of the TP53
checkpoint to individual ribosomopathies, and even different tissues
within a single ribosomopathy, is just beginning to be appreciated.
Therefore, stabilization of TP53 is still a possibility in other BCS patient
tissues or cell types.The fact that lymphoblastswere affected, while ﬁbroblasts were not,
supports thehypothesis that proper levels of EMG1 are critical in rapidly
proliferating cells. Slower-growing cells, such as ﬁbroblasts, have less of
a demand for ribosomes and therefore are not as strongly affected by
defects in ribosome biogenesis; thus the levels of EMG1 protein in
BCS patient ﬁbroblasts is likely adequate to allow normal rates of
Fig. 6. Protein synthesis rates and TP53 levels are unaffected in BCS patient cells. (A) Fibroblasts were incubated with 35S-cysteine/methionine to label newly synthesized protein, while
cycloheximidewas includedwith control cells to inhibit protein synthesis as a negative control. Proteinswere TCA-precipitated from cell lysates, ﬁltered, andwashed. Labeled proteinwas
detected using a liquid scintillation counter, protein concentration was determined, and counts per microgram of protein was calculated. No statistical difference was found. The mean of
three independent experiments and SEM are shown. (B) Lymphoblast lysates were probed by immunoblot using an anti-TP53 antibody, and β-actin is shown as a loading control. TP53
levels in the BCS cells were variable, and no statistically signiﬁcant differencewas found between control and BCS cell lines. A representative image from three independent experiments is
shown. (C) The presence of p21 in lymphoblast lysates was assessed by immunoblot using an anti-p21 antibody, and the same blot was probed for β-actin as a loading control. No signif-
icant difference between control and BCS cell lines was found.
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the embryo could be severely affected by a delay in 18S rRNA process-
ing, resulting in the developmental delay seen in BCS patients. The dif-
ferent results in lymphoblasts and ﬁbroblasts may also be a reﬂection
of the tissue speciﬁcity which is often seen in ribosome biogenesis dis-
orders. The preferential sensitivity of the lymphoblasts to a reduction
in EMG1 levels might be expected to result in immune system defects.
This has not been recorded in BCS patients, although several cases of
pneumonia, attributed to uncoordinated swallowing and aspiration,
were reported [1,2,4]. In BCS, thephenotypeprimarily affects the central
nervous system,making it likely that EMG1 deﬁciency has a greater im-
pact on the rapidly developing brain than it does on other tissues. These
tissue-speciﬁc presentations are common in the ribosomopathies and in-
dicate that studies of neural tissues may be required to demonstrate the
full impact of EMG1 deﬁciency on ribosomal biogenesis. Taken together,
these results conﬁrm conservation of EMG1 function in yeast and
human cells, and link BCS with the growing number of ribosomopathies.
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